The cybersecurity name fired off some punches at the competition and picked up another bolt-on acquisition amid earnings.
Shares of the provider of network security platforms could bump into a resistance zone after a strong start.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
CRM shouldn't be sagging with the broader tech sector.
I see VMW trading in the high $130s and my engine gets running.
Alexion Pharmaceuticals is a solid company that is the subject of acquisition rumors and Amicus Therapeutics has a key drug off to a strong start.
Salesforce is characteristically sustaining strength despite a heap of headwinds.